文献速递颈动脉与弓上血管

Medicare颈动脉支架国家覆盖决策对手术使用及血运重建后长期卒中风险的影响

Impact of the Medicare carotid stenting national coverage determination on procedure utilization and long-term stroke risk after carotid revascularization.
PubMed 文献 · J Vasc Surg · 2026-01-12

基于Truveta电子健康记录数据,研究2016至2024年接受TCAR、CEA或TFCAS的患者。2023年第三季度至2024年第四季度,TCAR和CEA手术率分别下降39.3%和38.4%,TFCAS仅增加2.1%。无症状患者8年无卒中生存率TCAR为87.2%、CEA为86.3%、TFCAS为79.8%。

要点

  • Medicare覆盖扩大后TFCAS使用基本未变,TCAR和CEA手术率反而下降。
  • 无症状患者长期卒中风险TCAR最低,TFCAS最高。
  • 需持续监测颈动脉血运重建手术使用趋势以优化患者结局。

核心结论

  • Medicare覆盖扩大后TFCAS使用基本未变,未对真实世界颈动脉实践产生实质影响。
  • TCAR和CEA手术率随时间下降,尽管其长期卒中风险较低。

研究设计与样本

  • 回顾性研究,使用Truveta电子健康记录数据,覆盖超过800家医院和1.2亿患者。
  • 纳入2016年1月至2024年12月接受TCAR、CEA或TFCAS的患者。
  • 采用中断时间序列分析评估2023年第三季度至2024年第四季度手术率变化。
  • 使用Kaplan-Meier分析和Cox回归比较无症状患者长期卒中风险。

主要发现

  • 共识别TCAR患者6473例(65.9%无症状)、CEA患者36224例(61.6%无症状)、TFCAS患者11626例(50.1%无症状)。
  • 2023年第三季度至2024年第四季度,每10万患者手术率TCAR下降39.3%(ITS P < .001),CEA下降38.4%(ITS P = .035),TFCAS增加2.1%(ITS P = .365)。
  • 无症状患者8年无卒中生存率:TCAR 87.2%(95%CI 84.0%-90.5%),CEA 86.3%(95%CI 85.5%-87.2%),TFCAS 79.8%(95%CI 77.6%-82.0%)。
  • 与CEA相比,TCAR调整后卒中风险比为0.83(95%CI 0.72-0.97),TFCAS为1.41(95%CI 1.27-1.56)。

临床怎么用

  • 临床决策应考虑TCAR和CEA在无症状患者中较低的长期卒中风险。
  • 需对颈动脉血运重建手术使用进行纵向监测以确保最佳结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In October 2023, Medicare expanded coverage for carotid stenting to include standard-risk beneficiaries, prompting substantial debate surrounding the potential impact on procedure use, most notably, for transfemoral carotid artery stenting (TFCAS). Since this coverage expansion, it remains unknown whether there has been a concordant change in carotid stenting use and resultant long-term stroke risk. Therefore, our objective was to document trends in procedure use of TFCAS, transcarotid artery revascularization (TCAR), and carotid endarterectomy (CEA) in response to the coverage expansion and compare the respective long-term stroke risks. METHODS: We performed a retrospective study using Truveta electronic health record data. Truveta provides daily updated electronic health record data from >800 hospitals and >120 million patients. We studied patients who underwent TCAR, CEA, or TFCAS from January 2016 to December 2024. We calculated the procedure rate for each quarter and performed an interrupted time series (ITS) analysis to assess the change from Q3 2023 (Medicare policy change) to Q4 2024. We used Kaplan-Meier analysis and Cox regression to compare the long-term stroke risk among asymptomatic patients. RESULTS: We identified 6473 TCAR patients (65.9% asymptomatic), 36,224 CEA patients (61.6% asymptomatic), and 11,626 TFCAS patients (50.1% asymptomatic). The procedure rate per 100,000 patients from Q3 2023 (Medicare policy change) to Q4 2024 decreased by 39.3% for TCAR (ITS P < .001) and 38.4% for CEA (ITS P = .035). The procedure rate increased by 2.1% for TFCAS (ITS P = .365). Among asymptomatic patients, the freedom from stroke at 8 years for TCAR, CEA, and TFCAS was 87.2% (95% confidence interval [CI], 84.0%-90.5%), 86.3% (95% CI, 85.5%-87.2%), and 79.8% (95% CI, 77.6%-82.0%), respectively. Compared with CEA, the adjusted hazard ratio of stroke was 0.83 (95% CI, 0.72-0.97) after TCAR and 1.41 (95% CI, 1.27-1.56) after TFCAS. CONCLUSIONS: TFCAS use has remained largely unchanged since the Medicare coverage expansion, refuting any perception that the Medicare policy shift would substantially impact real-world carotid practice. Interestingly, TCAR and CEA rates have decreased over time, despite having a lower long-term stroke risk. These findings highlight the need for longitudinal procedure use surveillance to ensure optimal outcomes among patients undergoing carotid revascularization.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Columbo JA, Stone DH, Zhao Y, et al. Impact of the Medicare carotid stenting national coverage determination on procedure utilization and long-term stroke risk after carotid revascularization. J Vasc Surg. 2026. PMID: 41534683. doi:10.1016/j.jvs.2025.12.347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。